Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

693 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Borden BA, Baca Y, Xiu J, Tavora F, Winer I, Weinberg BA, Vanderwalde AM, Darabi S, Korn WM, Mazar AP, Giles FJ, Crawford L, Safran H, El-Deiry WS, Carneiro BA. Borden BA, et al. Among authors: giles fj. Mol Cancer Ther. 2021 Jan;20(1):183-190. doi: 10.1158/1535-7163.MCT-20-0497. Epub 2020 Oct 21. Mol Cancer Ther. 2021. PMID: 33087512
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma.
Ryan KR, Giles F, Morgan GJ. Ryan KR, et al. Among authors: giles f. Eur J Haematol. 2021 Jan;106(1):90-99. doi: 10.1111/ejh.13525. Epub 2020 Oct 22. Eur J Haematol. 2021. PMID: 32997383
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Spriano F, Gaudio E, Cascione L, Tarantelli C, Melle F, Motta G, Priebe V, Rinaldi A, Golino G, Mensah AA, Aresu L, Zucca E, Pileri S, Witcher M, Brown B, Wahlestedt C, Giles F, Stathis A, Bertoni F. Spriano F, et al. Among authors: giles f. Blood Adv. 2020 Sep 8;4(17):4124-4135. doi: 10.1182/bloodadvances.2020001879. Blood Adv. 2020. PMID: 32882003 Free PMC article.
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Vatapalli R, Sagar V, Rodriguez Y, Zhao JC, Unno K, Pamarthy S, Lysy B, Anker J, Han H, Yoo YA, Truica M, Chalmers ZR, Giles F, Yu J, Chakravarti D, Carneiro B, Abdulkadir SA. Vatapalli R, et al. Among authors: giles f. Nat Commun. 2020 Aug 19;11(1):4153. doi: 10.1038/s41467-020-18013-7. Nat Commun. 2020. PMID: 32814769 Free PMC article.
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators. Hochhaus A, et al. Among authors: giles fj. Leukemia. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22. Leukemia. 2020. PMID: 32572189 Free PMC article. Clinical Trial.
Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD, Knox TM, Filic I, Soroko KM, Eschle BK, Wilkens MK, Gokhale PC, Giles F, Griffin A, Brown B, Shapiro GI, Zucconi BE, Cole PA, Lemieux ME, French CA. Morrison-Smith CD, et al. Among authors: giles f. Mol Cancer Ther. 2020 Jul;19(7):1406-1414. doi: 10.1158/1535-7163.MCT-20-0087. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371576
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. Patel SP, et al. Among authors: giles fj. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969335 Free PMC article.
Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.
Anraku T, Kuroki H, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar A, Giles FJ, Ugolkov A, Tomita Y. Anraku T, et al. Among authors: giles fj. Int J Mol Med. 2020 Feb;45(2):315-323. doi: 10.3892/ijmm.2019.4427. Epub 2019 Dec 12. Int J Mol Med. 2020. PMID: 31894292 Free PMC article.
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.
Kuroki H, Anraku T, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar AP, Giles FJ, Ugolkov A, Tomita Y. Kuroki H, et al. Among authors: giles fj. Sci Rep. 2019 Dec 27;9(1):19977. doi: 10.1038/s41598-019-56461-4. Sci Rep. 2019. PMID: 31882719 Free PMC article.
Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Jeffers A, Qin W, Owens S, Koenig KB, Komatsu S, Giles FJ, Schmitt DM, Idell S, Tucker TA. Jeffers A, et al. Among authors: giles fj. Sci Rep. 2019 Dec 12;9(1):18925. doi: 10.1038/s41598-019-55176-w. Sci Rep. 2019. PMID: 31831767 Free PMC article.
693 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page